SLC7A11 and ovarian carcinoma: Inhibition of PARP downregulated the expression of SLC7A11 in a p53-dependent manner to promote ferroptosis in ovarian cancer cells, revealing a previously unrecognized mechanism of PARP inhibitor therapy for ovarian cancer [27].